A double-blind, multicentre, international randomised study to assess the effects of 6 months or 12 months administration of strontium ranelate versus biphosphonates on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis
ISRCTN | ISRCTN50493318 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN50493318 |
EudraCT/CTIS number | 2006-005581-39 |
Secondary identifying numbers | CL3-12911-025 |
- Submission date
- 04/06/2007
- Registration date
- 12/07/2007
- Last edited
- 20/04/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Not provided at time of registration and not expected to be available in the future
Contact information
Scientific
INSERM Unité 831
Service de Rhumatologie et de Pathologie Osseuse Pavillon F
Hôpital E. Herriot
Lyon
69437
France
Study information
Study design | Double-blind double-dummy randomised controlled study |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A double-blind, multicentre, international randomised study to assess the effects of 6 months or 12 months administration of strontium ranelate versus biphosphonates on bone remodelling and bone safety assessed by histomorphometry in women with postmenopausal osteoporosis |
Study objectives | To assess the effects of 6 or 12 months treatment of strontium ranelate in comparison with biphosphonates on bone formation assessed by histomorphometry on transiliac paired biopsies performed in patients with postmenopausal osteoporosis treated for one year. |
Ethics approval(s) | First Ethics Committee approval obtained on 01/03/2007 in Milan, Italy (ref: 148) |
Health condition(s) or problem(s) studied | Postmenopausal osteoporosis in women |
Intervention | Intervention group: 2 g (one sachet) orally per day of strontium ranelate and one capsule of placebo for 6 or 12 months Control group: one capsule of bisphosphonates and one sachet of placebo for 6 or 12 months |
Intervention type | Other |
Primary outcome measure | Histomorphometry on paired transiliac biopsies performed at baseline and after treatment (cancellous mineralising surfaces). |
Secondary outcome measures | 1. Other histomorphometric parameters 2. Bone markers |
Overall study start date | 01/06/2007 |
Completion date | 31/12/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Female |
Target number of participants | 285 |
Total final enrolment | 387 |
Key inclusion criteria | 1. Women of at least 50 years of age 2. Postmenopausal for at least three years 3. Osteoporosis |
Key exclusion criteria | 1. Any medical or anatomical condition that potentially could put the patient at additional risk of an adverse event due to the biopsy procedure or that potentially could lead to an impossibility to perform a transiliac bone biopsy on each side 2. Previous and concomitant treatments interfering with bone metabolism |
Date of first enrolment | 01/06/2007 |
Date of final enrolment | 31/12/2009 |
Locations
Countries of recruitment
- Argentina
- Australia
- Belgium
- Brazil
- Canada
- Czech Republic
- Denmark
- Estonia
- France
- Hungary
- Italy
- Mexico
- Poland
- United Kingdom
Study participating centre
69437
France
Sponsor information
Industry
50 rue Carnot
Suresnes
92284
France
Website | http://www.servier.com/ |
---|---|
https://ror.org/034e7c066 |
Funders
Funder type
Industry
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | Yes |
IPD sharing plan summary | Available on request |
Publication and dissemination plan | Publication plan: Summary results are published on https://clinicaltrials.servier.com/. |
IPD sharing plan | The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com/ if a Marketing Authorisation has been granted after 1st January 2014. |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Basic results | No | No | |||
Basic results | 20/04/2020 | No | No |
Editorial Notes
20/04/2020: The following changes were made to the trial record:
1. Added clinicaltrialsregister.eu link to basic results (scientific).
2. The total final enrollment was added.
28/03/2018: Publication plan and IPD sharing statement amended.
24/01/2018: Publication plan and IPD sharing statement added.
04/12/2017: results summary added.